WO2005092367A1 - アディポネクチン分泌促進組成物 - Google Patents
アディポネクチン分泌促進組成物 Download PDFInfo
- Publication number
- WO2005092367A1 WO2005092367A1 PCT/JP2005/005851 JP2005005851W WO2005092367A1 WO 2005092367 A1 WO2005092367 A1 WO 2005092367A1 JP 2005005851 W JP2005005851 W JP 2005005851W WO 2005092367 A1 WO2005092367 A1 WO 2005092367A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conglycinin
- protein
- soybean
- adiponectin
- composition
- Prior art date
Links
- 102000011690 Adiponectin Human genes 0.000 title claims abstract description 46
- 108010076365 Adiponectin Proteins 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000028327 secretion Effects 0.000 title claims abstract description 28
- 230000001737 promoting effect Effects 0.000 title claims abstract description 20
- 108700037728 Glycine max beta-conglycinin Proteins 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 21
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 21
- 238000009825 accumulation Methods 0.000 claims abstract description 15
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 235000018102 proteins Nutrition 0.000 claims description 41
- 235000010469 Glycine max Nutrition 0.000 claims description 25
- 244000068988 Glycine max Species 0.000 claims description 19
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 13
- 108010083391 glycinin Proteins 0.000 description 9
- 229940001941 soy protein Drugs 0.000 description 9
- 230000037406 food intake Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000002949 phytic acid Nutrition 0.000 description 6
- 108010011619 6-Phytase Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229940068041 phytic acid Drugs 0.000 description 5
- 239000000467 phytic acid Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940085127 phytase Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000031787 nutrient reservoir activity Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 101710102211 11S globulin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000767750 Carya illinoinensis Vicilin Car i 2.0101 Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 101000767759 Corylus avellana Vicilin Cor a 11.0101 Proteins 0.000 description 2
- 101710190853 Cruciferin Proteins 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000622316 Juglans regia Vicilin Jug r 2.0101 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101000767757 Pinus koraiensis Vicilin Pin k 2.0101 Proteins 0.000 description 2
- 101000767758 Pistacia vera Vicilin Pis v 3.0101 Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007156 Resistin Human genes 0.000 description 2
- 108010047909 Resistin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000580 secretagogue effect Effects 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010079923 lambda Spi-1 Proteins 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition for promoting adiponectin secretion containing soybean j8-conglycinin as an active ingredient, and to the use of soybean ⁇ -conglycinin as an adiponectin secretion promoting composition.
- Visceral fat has a very high metabolic activity. When visceral fat accumulates, a large amount of free fatty acids as metabolites flows into the liver from the portal vein. This large amount of free fatty acids acts as a substrate for lipogenesis, directly promoting the synthesis of very low density lipoprotein (VLDL), and increasing the expression of the microsomal tolidarisideride transfer protein gene, the rate-limiting enzyme of VLDL synthesis. It is said that it promotes the assembly of VLDL and promotes its synthesis, leading to hyperlipidemia.
- VLDL very low density lipoprotein
- adipose tissue is a "secretory tissue” that secretes various physiologically active substances collectively called adipocytokines, which is not a mere temporary storage of energy (non-patented). Reference 2)).
- Adipocytic force-in includes TNF- ⁇ , which is involved in insulin resistance, leptin, angiotensinogen, which may be associated with hypertension, and PAI-1, which is an important regulator of the fibrinolytic system and promotes thrombus formation There is.
- TNF- ⁇ which is involved in insulin resistance
- leptin angiotensinogen
- PAI-1 which is an important regulator of the fibrinolytic system and promotes thrombus formation There is.
- Adiponectin has received the most attention in recent years.
- Adiponectin is a secretory protein specific to adipose tissue and has a collagen-like structure.
- Non-patent Documents 3 and 4 In a test using mice, it has been reported that adiponectin acts directly on atherosclerotic lesions mainly composed of macrophages and suppresses macrophage foaming and atherosclerosis.
- Non-patent Document 4 The blood concentration of adiponectin decreases with obesity, increases with weight loss, and is low in patients with the same obesity degree but also with diabetes and atherosclerotic diseases. It has been shown that adiponectin secretion is reduced in adipose tissue that has accumulated fat, which contributes to metabolic disorder syndrome (Non-Patent Document 3).
- Non-Patent Document 1 Metabolism 36, 54-59, 1987.
- Non-patent document 2 Annals of the New York Academy of Sciences 892, 146-154, 1999.
- Non-patent document 3 Matsuzawa, Soy Protein Research, 6, 1-10, 2003.
- Non-Patent Document 4 Shimomura, History of Medicine, 207, 647-652, 2003.
- Non-Patent Document 5 Takahashi, History of Medicine, 192,541-545, 2001.
- Non-Patent Document 6 Nagasawa A etc., Horm Metab Res., 34, 635-639, 2002.
- Non-Patent Document 7 Samoto, Biosci Biotechnol Bioche, 62, No. 5, 935-940, 1998.
- Non-Patent Document 8 Thahn, VH, and Shibasaki, K., J. Agric. FoodChem., 24, 117, 1976.
- Non-Patent Document 9 : Briggs, DR, and Mann, R ⁇ ., Cereal Chem, 27, 243 , 1950.
- Non-patent document 10 Wolf, WJ, and Sly.DA, Cereal Chem, 44, 653, 1967
- Non-patent document 11 Breeding Science, 46, 11, 1996.
- Non-Patent Document 12 Breeding Science, 50, 101, 2000.
- Non-Patent Document 13 SAITO, Biosci Biotechnol Bioche, 65, No. 4, 884-887, 2001.
- Patent Document 1 JP-A-55-124457
- Patent Document 2 JP-A-48-56843
- Patent Document 3 JP-A-49-31843
- Patent Document 4 JP-A-58-36345
- Patent Document 5 JP-A-6-187755
- Patent Document 6 U.S. Patent No. 6,171,640
- Patent Document 7 JP-A-5-86149
- Patent Document 8 JP-A-55-153562
- Patent Document 9 JP-A-56-64755
- Patent Document 10 JP-A-57-132844
- Patent Document 11 International Publication WO02Z28198
- an object of the present invention is to elucidate substances capable of promoting secretion of adiponectin, and to develop drugs and foods useful for treating and preventing various diseases based on the adiponectin secretagogue.
- soybean j8-conglycinin is one of the components of soybean protein, while examining various components that can solve the above problems. It was also found for the first time that intake of soybean j8-conglycine or highly purified soybean protein strongly enhanced blood adiponectin concentration.
- soybean conglycinin is used as an active ingredient of an adiponectin secretagogue, the accumulation of visceral fat is suppressed, thereby promoting the secretion of adiponectin in the blood and regulating the secretion of adiponectin, STNF and resistin.
- the present inventors have obtained the findings that improve insulin resistance and can be useful for suppressing the occurrence and progression of metabolic syndrome.
- a soybean j8 adiponectin secretion promoting composition containing conglycinin as an active ingredient
- composition according to the above which suppresses visceral fat accumulation and promotes adiponectin secretion.
- Soy Adiponectin secretion promoting composition containing soy protein containing at least 20% by weight of conglycinin per protein
- composition is adiponectin secretion promoting composition according to the above 1, wherein the composition is a food or an agent,
- composition as described in 1., wherein the composition is prepared so that conglycinin is consumed in an amount of 0.5 g or more per day.
- Soy 8—Use of conglycinin as a composition for promoting adiponectin secretion.
- composition of the present invention containing soybean ⁇ -conglycinin as an active ingredient has an effect of suppressing visceral fat accumulation and a high effect of promoting secretion of adiponectin. Therefore, by providing a functional agent or food or drink using the same, It can improve insulin resistance associated with adiponectin, and thus can be useful for 'improving' treatment of various disease states such as arteriosclerosis derived from metabolic syndrome.
- development of a new use of soybean j8-conglycinin can further expand the range of use of soybean protein containing soybean conglycin with high purity as a health material.
- composition for promoting adiponectin secretion of the present invention is characterized by using soybean ⁇ -conglycinin as an active ingredient.
- soybean ⁇ -conglycinin as an active ingredient.
- Soy j8-conglycinin (hereinafter, simply referred to as "j8-conglycinin"), which is an active ingredient of the present invention, is similar to glycinin (also referred to as 11S globulin) and is a storage protein of legumes such as soy. Is a major protein component that is said to be contained in large amounts. It has been found that its content is actually quite low.
- the ratio of ⁇ -conglycinin (also referred to as 7S globulin) to glycinin is about 1: 2, but in fact, isolated soy protein produced industrially due to the presence of lipid-associated proteins. Occupy about 35% (Non-Patent Document 7). This indicates that j8-conglycinin is only about 20% in soy protein.
- the storage protein of soybeans precipitates at around pH 4.5 and can be relatively easily separated into a whey fraction and a protein fraction.
- This storage protein is referred to as isolated soy protein, and many uses in the food industry are made in this form.
- Proteins are also classified into 2S, 7S, US, and 15S globulins based on the sedimentation constant obtained by ultracentrifugation analysis. Of these, 7S and 11S are the major constituent protein components of the globulin fraction.
- 7S globulin and 11S globulin are classified by the precipitation method and substantially correspond to ⁇ -conglycinin and glycinin in immunological nomenclature. Both have various different properties such as viscosity, coagulation and surface activity. Therefore, by fractionating soy protein into a j8-conglycinin-rich fraction and a glycinin-rich fraction, it is possible to utilize the properties of both proteins, and it is expected to expand the field of protein utilization in industry. .
- ⁇ -conglycinin is composed of three types of subunits, ⁇ and ⁇ , and the amount of ⁇ -conglycin refers to the total amount of a; and a j8 subunits.
- the ratio of ⁇ -conglycinin: glycinin is typically expressed by the area ratio of the pattern obtained by SDS-polyacrylamide gel electrophoresis (hereinafter referred to as SDS-PAGE) by densitometry. 1: 2.
- SDS-PAGE SDS-polyacrylamide gel electrophoresis
- the purity of 13-conglycinin was determined by the method of SDS-PAGE (Laemmli. Nature., 227, 680 (1970)). Analyze on gels. The applied amount is 10 g, the migration pattern obtained by the above SDS-PAGE is measured with a densitometer, and the area ratio of ⁇ -conglycinin to the whole is defined as ⁇ -conglycinin purity.
- ⁇ -conglycinin is not particularly limited as to soybean as a raw material depending on the place of origin, kind or preparation method. Soybean power extraction 'from the isolated soybean protein) fractionation of a fraction highly containing 8-conglycinin, It is obtained by extracting and separating from soybeans containing ⁇ -conglycine with high purity.
- the method of fractionating ⁇ -conglycinin from soybean protein is not particularly limited as long as a known method is used. Specifically, it can be prepared, for example, as follows. Monkey
- Non-Patent Document 9 Cooling insoluble classification method using cryoprecipitation
- Patent Document 2 A method utilizing the difference in reactivity with calcium (Patent Document 2, Non-Patent Document 10)
- Patent Document 3 Method of utilizing the difference in solubility in ⁇ ionic strength
- Patent Document 5 Cooling down phenomenon and method using a reducing agent etc.
- Non-Patent Document 11 Method of separating protein from glycinin-deficient soybeans by breeding, that is, seeds rich in / 3 conglycinin (Non-Patent Document 11) (Non-Patent Document 12, Patent Document 6)
- Patent Documents 7 to 10 Others (Patent Documents 7 to 10)
- j8-conglycinin can be prepared by an ordinary method for producing isolated soybean protein.
- 8-conglycinin protein containing at least 40% of j8-conglycinin per protein is obtained.
- j8-conglycinin protein containing at least 40% as j8-conglycinin per protein it is possible to set the j8-conglycinin content more efficiently.
- j8-conglycyl of a purity sufficient for use without using a reducing agent A wider range of applications can be expected by using a method in which nin can be fractionated.
- an enzyme or an enzyme agent such as phytase phosphatase having phytate degrading activity is added to the obtained conglycinin-based fraction.
- phytic acid is decomposed and removed to 1.2% or less, preferably 0.2% or less, more preferably 0.1% or less per protein.
- a method for removing lipid-associated protein to 10% or less it is possible to perform heating in a slightly acidic region where lipid-associated protein is easily insolubilized and remove it as a precipitate fraction (see Patent Document 11). .
- those prepared according to the method of separating j8-conglycinin and glycinin from defatted soybean using phytase also have a high ⁇ -conglycinin content and are preferable (for example, see Non-Patent Document 13).
- the purity of i ⁇ conglycinin, ie, 13 conglycinin, which is fractionated by any of the above methods is 20% or more, preferably 40% or more, and more preferably 60% or more. % Or more, more preferably 80% or more, and most preferably 90% or more.
- composition of the present invention refers to an agent or a food.
- the active ingredient is used alone or in admixture with a pharmaceutically acceptable carrier in various dosage forms and various dosage forms.
- the carrier used here is acceptable for formulation, and various additives commonly used for ordinary drugs, such as fillers, binders, disintegrants, surfactants, lubricants, diluents, Formulation can be carried out by using excipients, stabilizers, preservatives, wetting agents, sweeteners, coloring agents, flavors, tonicity adjusting agents, buffers, antioxidants, ⁇ adjusters and the like.
- the dosage form is not particularly limited and can be appropriately selected depending on the purpose of the treatment.
- solid preparations such as tablets, hard capsules, soft capsules, granules, powders, and pills, It can be administered in the form of a solution, suspension, emulsion, solution and the like.
- parenteral In the case of target administration, it is administered in the form of injection solution, suppository and the like. Oral administration is desirable.
- composition of the present invention is a food, an oil-in-water emulsified food such as a cream, which is a common food form; a water-in-oil emulsified food such as margarine; an edible oil; a soft drink, a tea-based beverage Dairy products such as milk, cheese, and yogurt; soy products such as soy milk, fermented soy milk, soy protein drinks, tofu, natto, fried, thick fried, ganto, etc .; hamburger, meatball, tang Processed meat products such as fried and nugget; various types of vegetables; baked goods, chocolate, cake, frozen dessert, cereals, candy, gum, tablets, etc .; breads such as bread, confectionery bread, donut; rice, sushi, rice cake And other foods such as cooked rice.
- ⁇ -conglycinin can be easily measured for its content in foods, it can be used as an active ingredient (involved ingredient) in the food itself or in food packaging, containers, labels, advertisements, brochures, etc. It has the effect of suppressing the accumulation, so it is suitable for preventing or ameliorating diseases related to visceral fat accumulation, "j8-Conglycinin is contained as an active ingredient", ") 8-Effective intake of conglycinin", etc.
- Foods for health use such as foods for specified health use, which are directly displayed, can also be used.
- indirect labeling that suggests that ingesting the food is effective in preventing or ameliorating a disease associated with visceral fat accumulation may be effective. Labeled foods such as LV, food for health use are also included in the present invention.
- the effective amount of the obtained adiponectin secretion-promoting composition may be appropriately determined depending on the usage, age, gender and other conditions of the subject or animal to be administered, degree of disease, purpose, etc.
- the daily dose of j8-conglycinin should be in the range of about 0.5 to about LOg, and the dosage should be in relation to the content in the composition to satisfy the powerful range. Should be set.
- ⁇ -conglycinin is a fractionated and purified soybean, so there is almost no concern about side effects. It does not preclude setting a range that exceeds the upper and lower limits.
- the above composition can be administered once or twice to four times a day.
- the 13-conglycinin content in the composition of the present invention is preferably from 0.5 to: L00% by weight. Yo More preferably, it is suitable to be blended at 2.5 to 80% by weight.
- composition of the present invention When the composition of the present invention is ingested, the accumulation of visceral fat is suppressed, whereby the secretion of adiponectin in the blood is promoted, and an improvement in insulin resistance can be expected.
- treatment, prevention or amelioration of diseases such as hyperlipidemia, diabetes, obesity, and hypertension can be achieved, and the occurrence of arteriosclerosis can be prevented.
- the main analysis methods used in the present invention are as follows.
- Crude protein The nitrogen content was determined based on the Kehldahl method, and converted to crude protein by multiplying by a coefficient of 6.25.
- SPE standard The migration pattern obtained by the SDS-polyacrylamide electrophoresis was measured as an area with a densitometer, and the ratio of the area of the relevant fraction to the total area was defined as the purity (SPE standard).
- j8 - conglycinin content alpha refers to the total amount of a beta subunit
- glycinin containing amount refers to the total amount of acidic polypeptides (Alpha) and basic polypeptides (beta).
- the purity may be determined by the corrected purity in consideration of the amount of the lipid-associated protein mixed therein, as described below. However, in the present application, the purity was determined according to the SPE standard.
- the solution temperature during this centrifugation was around 25 ° C.
- the soluble fraction was adjusted to pH 4.9 with hydrochloric acid and centrifuged to obtain a precipitated card.
- the precipitated curd was hydrolyzed (4 times the weight), washed with 10 volumes of water, neutralized with caustic soda, sterilized at 140 ° C for 15 seconds, and immediately spray dried and phytase treated j8-conglycinin protein. I got white.
- the low-phytin j8-conglycinin protein obtained in this manner is subjected to SDS polyacrylamide gel electrophoresis, and the purity of the stained protein band is determined to be 90% as a result of measurement.
- the phytic acid content was 0.05% per protein, and it was confirmed that phytic acid was almost completely decomposed and removed.
- the oral meta-oil content of this product was 0.5%, confirming that it was significantly reduced.
- each group was laparotomized under Nembutal anesthesia and blood was collected from the abdominal aorta. After heparin treatment, the blood was centrifuged at 3000 rpm for 15 minutes, and the obtained plasma was immediately frozen and used as a blood sample. Livers were removed immediately after dissection and stored frozen at -80 ° C until analysis. The concentration of adiponectin in the collected blood was analyzed using an adiponectin analysis kit for mice and rats (Otsuka Pharmaceutical Co., Ltd.). The results are shown in FIG. ⁇ -conglycinin increased blood adiponectin levels.
- j8-conglycinin protein powder obtained in Production Example 1 50 parts of j8-conglycinin protein powder obtained in Production Example 1, 43 parts of maltose, 3 parts of citrate, 3 parts of emulsifier, and 1 part of flavor are mixed and pressurized to 4 mm to 20 mm ⁇ with a rotary tableting machine.
- ⁇ -conglyci Tablets were similarly prepared using sodium caseinate instead of nin powder.
- Example 1 The tablets prepared in Example 1 using the
- the subcutaneous fat area and the visceral fat area were automatically calculated by using a FatPointer (manufactured by Hitachi Medical) for the cross section of the umbilicus using ROBUSTO_Multi manufactured by Sharp. Table 3 shows the subject's profile.
- FIG. 2 shows a change in visceral fat area
- FIG. 3 shows a change in subcutaneous fat area.
- the visceral fat area force S from 163.2 to 14.1 cm2 to 154.1 to 14.9 cm2
- the subcutaneous fat area from 176.5 to 32.5 cm2 to 161.1 ⁇ 25.3 cm2 Diminished.
- FIG. 4 shows a change in CT girth
- FIG. 5 shows a change in BMI calculated from body measurements.
- the CT girth decreased from 95.5 ⁇ 3.6cm to 93.3 ⁇ 3.1cm
- the BMI decreased from 28.1 ⁇ 1.6 to 27.5 ⁇ 1.4 after 6 months of test food intake compared to the value before the test, resulting in a decrease in visceral fat.
- FIG. 6 shows changes in blood adiponectin before and after the test.
- Adiponectin is visceral fat It is known to be inversely correlated with fat accumulation.
- the blood adiponectin level was 4.07 persons 0.34 / zg / ml power 4.17 ⁇ 0.34 / zg / ml
- the test diet increased 6 months after ingestion compared to the pre-test value and increased the visceral fat-reducing effect compared to the pre-test value. This was supported by the Inn's point of view. Brief Description of Drawings
- FIG. 1 is a graph comparing the effects of ⁇ -conglycinin, isolated soybean protein and casein on blood adiponectin concentration.
- FIG. 2 is a graph showing changes in visceral fat area due to ingestion of ⁇ -conglycinin.
- FIG. 3 is a graph showing changes in subcutaneous fat area due to ingestion of ⁇ -conglycinin.
- FIG. 4 is a graph showing changes in abdominal CT girth due to ingestion of ⁇ -conglycinin.
- FIG. 5 is a graph showing changes in ⁇ due to ingestion of ⁇ -conglycinin.
- FIG. 6 is a graph showing changes in blood adiponectin concentration due to ingestion of ⁇ -conglycinin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511575A JPWO2005092367A1 (ja) | 2004-03-29 | 2005-03-29 | アディポネクチン分泌促進組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-094729 | 2004-03-29 | ||
JP2004094729 | 2004-03-29 | ||
JP2005-068792 | 2005-03-11 | ||
JP2005068792 | 2005-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092367A1 true WO2005092367A1 (ja) | 2005-10-06 |
Family
ID=35055990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005851 WO2005092367A1 (ja) | 2004-03-29 | 2005-03-29 | アディポネクチン分泌促進組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005092367A1 (ja) |
WO (1) | WO2005092367A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069716A1 (ja) * | 2005-12-16 | 2007-06-21 | Nippon Suisan Kaisha, Ltd. | 内臓脂肪蓄積抑制作用を有する組成物 |
WO2007138749A1 (ja) * | 2006-05-31 | 2007-12-06 | Snow Brand Milk Products Co., Ltd. | 内臓脂肪蓄積抑制剤及び、血中アディポネクチン濃度増加促進及び/又は減少抑制剤 |
JP2012158553A (ja) * | 2011-02-01 | 2012-08-23 | Gunze Ltd | 内臓脂肪蓄積抑制剤 |
JP2017020835A (ja) * | 2015-07-08 | 2017-01-26 | 花王株式会社 | 食品に対する内臓脂肪のつきにくさの評価方法 |
JP7228211B1 (ja) * | 2022-04-26 | 2023-02-24 | 株式会社みすずコーポレーション | 肉様大豆加工食品及びそれを含む加工食品 |
WO2023210034A1 (ja) * | 2022-04-26 | 2023-11-02 | 株式会社みすずコーポレーション | 肉様大豆加工食品及びそれを含む加工食品 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026243A1 (fr) * | 2000-09-29 | 2002-04-04 | Fuji Oil Company, Limited | Composition permettant de reduire les graisses neutres dans le sang |
WO2003016906A1 (fr) * | 2001-08-17 | 2003-02-27 | Rebio Gen, Inc. | Procede de diagnostic ou de controle d'une erreur du metabolisme du saccharose |
JP2003284504A (ja) * | 2002-03-29 | 2003-10-07 | Fuji Oil Co Ltd | 大豆7sたん白を含有する賦型食品及びその製造法 |
JP2004049124A (ja) * | 2002-07-19 | 2004-02-19 | Fuji Oil Co Ltd | 大豆7sたん白含有タブレット |
-
2005
- 2005-03-29 WO PCT/JP2005/005851 patent/WO2005092367A1/ja active Application Filing
- 2005-03-29 JP JP2006511575A patent/JPWO2005092367A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026243A1 (fr) * | 2000-09-29 | 2002-04-04 | Fuji Oil Company, Limited | Composition permettant de reduire les graisses neutres dans le sang |
WO2003016906A1 (fr) * | 2001-08-17 | 2003-02-27 | Rebio Gen, Inc. | Procede de diagnostic ou de controle d'une erreur du metabolisme du saccharose |
JP2003284504A (ja) * | 2002-03-29 | 2003-10-07 | Fuji Oil Co Ltd | 大豆7sたん白を含有する賦型食品及びその製造法 |
JP2004049124A (ja) * | 2002-07-19 | 2004-02-19 | Fuji Oil Co Ltd | 大豆7sたん白含有タブレット |
Non-Patent Citations (3)
Title |
---|
KATSUKI A. ET AL: "Plasma levels of adiponectin are associated with insulin resistance and serum levels of triglyceride in Japanese metabolically obese, normal-weight men with normal glucose tolerance.", DIABETES CARE., vol. 26, no. 10, 2003, pages 2964 - 2965, XP002989871 * |
MANDEEP B. ET AL: "Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Piglitazone-Treated Type 2 Diabetic Patients.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM., vol. 89, no. 1, 2004, pages 200 - 206, XP002989872 * |
NAGASAWA A. ET AL: "Divergent effect of soy proteindiet on the expression of adipocytokines.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 311, 2003, pages 909 - 914, XP004472255 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069716A1 (ja) * | 2005-12-16 | 2007-06-21 | Nippon Suisan Kaisha, Ltd. | 内臓脂肪蓄積抑制作用を有する組成物 |
WO2007138749A1 (ja) * | 2006-05-31 | 2007-12-06 | Snow Brand Milk Products Co., Ltd. | 内臓脂肪蓄積抑制剤及び、血中アディポネクチン濃度増加促進及び/又は減少抑制剤 |
JP2012158553A (ja) * | 2011-02-01 | 2012-08-23 | Gunze Ltd | 内臓脂肪蓄積抑制剤 |
JP2017020835A (ja) * | 2015-07-08 | 2017-01-26 | 花王株式会社 | 食品に対する内臓脂肪のつきにくさの評価方法 |
JP7228211B1 (ja) * | 2022-04-26 | 2023-02-24 | 株式会社みすずコーポレーション | 肉様大豆加工食品及びそれを含む加工食品 |
WO2023210034A1 (ja) * | 2022-04-26 | 2023-11-02 | 株式会社みすずコーポレーション | 肉様大豆加工食品及びそれを含む加工食品 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005092367A1 (ja) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5688818B2 (ja) | 栄養組成物 | |
EP2384125B1 (en) | Protein hydrolysate compositions having enhanced cck releasing ability | |
US20100190708A1 (en) | Composition for amelioration of body lipid | |
EP2253324A1 (en) | Use of a casein-derived peptide and compositions thereof as antihypertensive | |
EP1874140B1 (en) | Peptides having a health benefit and compositions comprising them | |
KR20080049330A (ko) | 포만감을 증가시키는 식품 조성물 | |
EP1941899A1 (en) | Agent for promoting glucagon-like peptide 1 secretion, food or drink for promoting glucagon-like peptide 1 secretion, agent for inhibiting postprandial increase in blood sugar level and food or drink for inhibiting postprandial increase in blood sugar level | |
EP2420244A1 (en) | Lipid metabolism-improving agent | |
WO2005092367A1 (ja) | アディポネクチン分泌促進組成物 | |
JP4809785B2 (ja) | 醤油に含まれる高分子物質の用途 | |
AU2005302921B2 (en) | Protein hydrolysate with antidiabetic effect | |
JP2006347946A (ja) | 成長ホルモン分泌促進組成物 | |
JP4461680B2 (ja) | 血中中性脂肪低減用組成物 | |
JPWO2019058609A1 (ja) | エネルギー消費促進用組成物 | |
Luhovyy et al. | Food proteins in the regulation of blood glucose control | |
WO2006101181A1 (ja) | 肝機能障害予防もしくは改善組成物、及び肝機能障害予防もしくは改善法 | |
JP2005006533A (ja) | 機能性食品、その製造方法及び医薬 | |
WO2004087199A1 (ja) | インスリン抵抗性改善用組成物 | |
US20070299000A1 (en) | Method of lowering body fat percentage or inhibiting body fat percentage increase | |
JP2001026753A (ja) | 高血圧症予防又は治療用組成物 | |
KR20230115233A (ko) | 콩 유래 가수분해물을 유효성분으로 포함하는, 근육 질환 치료 또는 운동수행능력 향상용 약학적 조성물 | |
JP2006219420A (ja) | 抗高血圧剤 | |
US20080124449A1 (en) | Food for Preventing Life Style-Related Diseases | |
KR101830480B1 (ko) | 메틸 리놀렌산염을 포함하는 고중성지방혈증의 예방 또는 치료용 약학적 조성물 | |
JP6061270B2 (ja) | 米アルブミンを含有する血糖降下剤及び健康食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006511575 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |